Forum Financial Management LP grew its stake in shares of Danaher Corporation (NYSE:DHR – Free Report) by 212.2% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 8,776 shares of the conglomerate’s stock after acquiring an additional 5,965 shares during the period. Forum Financial Management LP’s holdings in Danaher were worth $1,944,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently made changes to their positions in the company. BlackRock Inc. purchased a new position in shares of Danaher in the second quarter worth about $10,492,520,000. Jupiter Topco LLC bought a new position in shares of Danaher in the second quarter worth $1,456,317,000. Generation Investment Management LLP purchased a new stake in shares of Danaher in the 2nd quarter valued at about $1,287,949,000. Bank of America Corp DE purchased a new stake in Danaher in the second quarter valued at approximately $993,846,000. Finally, Legal & General Group Plc bought a new stake in shares of Danaher during the 2nd quarter worth $801,056,000. Institutional investors own 79.05% of the company’s stock.
Danaher Price Performance
NYSE DHR opened at $228.87 on Friday. The company has a 50-day moving average price of $214.04 and a 200-day moving average price of $195.97. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $160.89 billion, a P/E ratio of 40.65, a PEG ratio of 2.91 and a beta of 0.76. Danaher Corporation has a 52 week low of $160.93 and a 52 week high of $242.80.
Danaher (NYSE:DHR – Get Free Report) last released its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, topping the consensus estimate of $1.85 by $0.09. The business had revenue of $6.26 billion for the quarter, compared to the consensus estimate of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The company’s quarterly revenue was up 5.5% on a year-over-year basis. During the same period last year, the firm earned $0.77 earnings per share. Equities research analysts anticipate that Danaher Corporation will post 8.53 earnings per share for the current year.
Danaher Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a $0.40 dividend. This represents a $1.60 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Danaher’s dividend payout ratio is currently 28.42%.
Wall Street Analysts Forecast Growth
A number of analysts recently weighed in on DHR shares. Wall Street Zen upgraded Danaher from a “hold” rating to a “buy” rating in a research report on Saturday, October 10th. Morgan Stanley boosted their target price on Danaher from $220.00 to $240.00 and gave the company an “overweight” rating in a research note on Monday. Barclays lifted their price objective on Danaher from $230.00 to $255.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. Evercore reissued an “outperform” rating and set a $230.00 price objective on shares of Danaher in a research note on Monday, July 6th. Finally, Royal Bank Of Canada lifted their price objective on Danaher from $215.00 to $250.00 and gave the company an “outperform” rating in a research note on Monday, October 5th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, Danaher has an average rating of “Moderate Buy” and a consensus price target of $235.41.
View Our Latest Research Report on DHR
Danaher Company Profile
Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.
The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.
Featured Stories
- Five stocks we like better than Danaher
- Bank of America Stock Sell-Off Looks Like a Buying Opportunity
- AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff?
- GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking
- Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.
